Mike Tillinger is a patient-centric, seasoned medical leader, with over twenty years of pharmaceutical industry experience in Clinical Development & Medical Affairs. Mike led global programs across numerous therapeutic areas including rare disease, neurology, pain, critical care, hematology, rheumatology, pulmonology, gastroenterology, RNA editing, etc.

Mike has been a consultant since April 2024, developing protocols and managing studies at various companies. Prior to consulting, Mike was the VP or Clinical Development at Wave life sciences, where he was responsible for the strategic development of a platform of oligonucleotides (ASO) across several rare diseases.

Mike’s industry experience spans small, medium and large pharmaceuticals and biotech companies.

Mike received his MD from the Tel Aviv University and is board certified in anesthesiology.